Who Is a Candidate for CyberKnife? Tumor Size, Location and Prior Treatment Explained

The scan report says the spot in her left lung has grown by two millimeters. Her surgeon has already explained why another operation would be risky after the lobectomy she had years ago, and a friend has mentioned a robotic radiation treatment she saw on a hospital billboard. Sitting at the kitchen table with the report and a cold cup of tea, she types the question millions of people have typed before her: who is a candidate for CyberKnife?

The honest answer is more interesting than a yes or no. Candidacy is decided by a set of measurable things, how big the tumor is, where it sits, what has already been done to it, and how well the rest of the body is doing, weighed together by a team who sees the whole picture.

This explainer walks through each of those factors the way a radiation oncologist would, so the conversation in the consulting room feels less like a lottery and more like a plan.

What CyberKnife actually is, and why candidacy is about the tumor, not the machine

CyberKnife is the brand name of one particular robotic system used to deliver stereotactic radiosurgery. Stereotactic radiosurgery, usually shortened to SRS, is a way of giving a high dose of radiation to a precisely mapped target in one to five sessions rather than spreading a lower dose across many weeks (Mayo Clinic). When the same idea is applied outside the head, to the lung, spine, liver, pancreas or prostate, it is often called stereotactic body radiation therapy, or SBRT.

Despite the name, nothing is cut. The word “knife” refers to the sharpness of the radiation beam’s edge, the way dose falls off steeply at the border of the target so that neighboring tissue receives comparatively little (MedlinePlus).

This matters for anyone asking about eligibility, because the medical question is never really “can this machine treat me?” but “is stereotactic radiation the right tool for this tumor, in this person, at this moment?” Several manufacturers build equipment capable of SRS and SBRT, and the criteria clinicians apply are broadly the same regardless of the logo on the side. A robotic arm, a specialized linear accelerator with image guidance, or a fixed-frame cobalt system can all deliver the highly focused dose; each has strengths in particular situations, and a treatment center will typically use what it has and what fits the case.

So when this article says “a candidate for CyberKnife,” read it as “a candidate for robotic stereotactic radiosurgery or SBRT.” The decision is usually made at a multidisciplinary tumor board, a regular meeting where radiation oncologists, surgeons, medical oncologists, radiologists and pathologists review cases together. That collective judgment, not a single specialist’s preference, is where candidacy is settled.

How CyberKnife treatment works, step by step

Understanding the mechanics explains most of the eligibility rules, so it is worth a short tour.

Everything begins with imaging. A planning CT scan, often fused with MRI or PET images, lets the team draw the exact outline of the tumor and the organs at risk around it. In the brain, a lightweight mesh mask molded to the face keeps the head in a consistent position; no screws or metal frame are attached to the skull with this type of system (MedlinePlus). For tumors in the chest or abdomen, which move as a person breathes, tiny gold markers called fiducials are sometimes placed in or near the tumor beforehand so the machine can track it in real time. Fiducials are simply small radiopaque seeds, visible on X-ray, that act as landmarks.

Planning follows, usually over several days. Physicists and dosimetrists design a beam arrangement, often hundreds of individual beams converging from many angles, so that the dose piles up inside the target and stays low everywhere else.

On treatment day the patient lies on a couch while the robotic arm moves around them, pausing to deliver each beam. Paired X-ray cameras take images throughout the session; if the target has shifted by even a millimeter or two, the robot corrects its aim before the next beam. Sessions typically last from about 30 minutes to a couple of hours, and most people go home the same day (MedlinePlus).

The radiation itself damages the DNA of cells in the target. Cancer cells tend to be poor at repairing that damage and die over subsequent weeks and months; a benign tumor may simply stop growing rather than shrink dramatically (Mayo Clinic). That delayed effect is why follow-up imaging, rather than the day of treatment, tells the real story.

Who is a candidate for CyberKnife? The four questions a tumor board asks

Strip away the technology and eligibility comes down to four questions that a tumor board works through in roughly this order.

Can we see it clearly? Stereotactic radiation requires a target that imaging can define with sharp edges. A discrete nodule, a well-circumscribed meningioma or a single spinal metastasis qualifies. A tumor that infiltrates diffusely, or disease that is scattered microscopically through an organ, does not give the planning team a boundary to aim at (Johns Hopkins Medicine).

Is it small enough? High doses delivered in few sessions are safe only when the volume receiving that dose is limited. The next section explains why, but the short version is that size is the single most common reason a person is offered conventional radiation or surgery instead.

Where is it, and what is next to it? Tumors near the optic nerves, brainstem, spinal cord, bowel or major airways are often the very cases where the steep dose fall-off of SRS is most valuable, yet those same neighbors set limits on how much dose can be given (Mayo Clinic).

What is the goal, and how is the rest of the body doing? Stereotactic treatment can be used with the aim of controlling a tumor for the long term, of relieving pain from a spinal metastasis, or of treating a handful of metastases in someone whose systemic therapy is otherwise keeping cancer in check. Each goal carries different eligibility thresholds. Overall fitness matters too, though less than for surgery, because there is no anesthesia and no incision to heal.

People who answer all four favorably are the classic candidates: small, well-defined lesions, often in awkward locations, in a person who wants or needs to avoid an operation. People who answer one or two unfavorably are not excluded automatically; they simply need a longer conversation.

Tumor size: why "small" is the word that matters most

Radiation oncologists think about size in two ways: the diameter you can read off a scan, and the volume of normal tissue that will unavoidably receive some dose.

Here is the physics in plain language. Every beam has to travel through healthy tissue to reach the target. When the target is small, the total volume of surrounding tissue exposed to a meaningful dose is small too, and the body can tolerate a very high dose in a single visit. Double the diameter of a tumor and you increase its volume roughly eightfold, and the collar of healthy tissue around it grows accordingly. At some point the risk of injuring that collar outweighs the advantage of finishing quickly.

For that reason, brain radiosurgery in a single session has traditionally been reserved for tumors around 3 centimeters or smaller, about the width of a walnut; Mayo Clinic describes SRS as generally most suitable for small tumors. Larger lesions are often treated with the same technology but split into three to five sessions, an approach sometimes called fractionated stereotactic radiotherapy, which gives normal tissue time to recover between visits (Mayo Clinic). Beyond a certain size, conventional radiation over several weeks, surgery, or surgery followed by radiation to the cavity becomes the better plan.

Outside the brain, thresholds vary by organ. A lung nodule surrounded by air is more forgiving than a liver tumor pressed against bowel, because air tolerates dose better than intestine does. The spine is judged by how much of the cord sits in the high-dose zone rather than by tumor width alone.

The practical message for a person reading a scan report: a measurement of a few centimeters usually keeps the door open, a measurement approaching the width of a tennis ball usually points toward a different first step, and the team will make the call from the full three-dimensional picture rather than one number.

Tumor location: where pinpoint accuracy earns its keep

Location cuts both ways. It is often the reason someone is referred for stereotactic treatment in the first place, and it is also the factor that most often shapes how many sessions they will need.

Consider the brain. Tumors in the brainstem, at the base of the skull or wrapped around the optic nerves are places where a scalpel carries real risk of lasting harm. Stereotactic radiosurgery has become a standard option for several conditions in exactly these areas: small brain metastases, acoustic neuromas (a benign growth on the hearing and balance nerve), meningiomas (a usually benign tumor of the brain’s covering), pituitary adenomas and arteriovenous malformations, which are tangles of abnormal blood vessels (Mayo Clinic; Johns Hopkins Medicine). Trigeminal neuralgia, a severe facial pain condition, is also treated with radiosurgery aimed at the nerve rather than at a tumor.

The spine is a second sweet spot. A metastasis in a vertebra sits millimeters from the spinal cord; the ability to shape dose around the cord while treating the bone is the entire point of the technology. Real-time tracking is also what makes moving targets in the lung, liver, pancreas and prostate feasible; a tumor that rises and falls with each breath would otherwise require a much larger safety margin.

Location also sets ceilings. The spinal cord, optic pathways, brainstem and small bowel each have a well-documented tolerance for dose in a single session. If a tumor hugs one of these structures too tightly, the team may choose more sessions at a lower dose per visit or a different treatment altogether. A tumor that has already caused a fracture, or one compressing the spinal cord and producing weakness, often needs a surgeon first and radiation second.

In short, awkward location tends to make someone a better candidate, right up until the moment it makes the target impossible to treat safely.

Prior radiation: can you be treated again in the same area?

Few questions come up more often in the consulting room than this one, and few have a more genuinely nuanced answer.

Normal tissue remembers radiation. Conventional radiotherapy delivers a total dose that is calculated to sit just below what the healthy organs in the field can tolerate over a lifetime. When cancer returns inside a previously treated area, the tumor may be vulnerable to more radiation, but the surrounding tissue has already spent much of its budget.

Stereotactic radiation changes the arithmetic. Because dose falls away so steeply at the target’s edge, the volume of previously irradiated tissue that receives a second significant dose can be kept far smaller than with a broad conventional field. This is why re-irradiation, the medical term for treating an area a second time, is one of the situations where robotic SRS and SBRT are most often considered (Johns Hopkins Medicine).

Eligibility here depends on details the patient rarely knows offhand but the team can retrieve: the exact dose delivered before, how long ago, which structures were in the beam and how they have recovered. Longer gaps generally allow more recovery, though the relationship is not linear and differs by organ. The spinal cord, for instance, is treated with particular caution because injury there is irreversible.

People are sometimes surprised to learn that having had radiation elsewhere in the body, say to the breast years ago and now to a single brain metastasis, has essentially no bearing on candidacy. Radiation does not accumulate in the bloodstream; it affects only the tissue it passes through. Prior radiation to a different region is a footnote in the planning meeting, not a barrier.

The decision on re-irradiation is always individualized, and a person who is told it is not advisable at one point may become a candidate later as tissue recovers or as goals change.

Prior surgery, chemotherapy and other treatments already under way

Most people who reach a radiosurgery consultation have already had something done, and each type of earlier treatment interacts with candidacy differently.

Surgery. A previous operation is often a reason for referral rather than an obstacle. After a brain metastasis is removed, radiation to the surgical cavity is commonly recommended to reduce the chance of regrowth at the margin, and stereotactic delivery to that cavity is one standard approach (Johns Hopkins Medicine). Scar tissue and altered anatomy do complicate planning, so the team will want operative notes and post-operative imaging. In the chest, prior lung surgery that leaves someone unable to tolerate another operation is a textbook scenario in which SBRT is considered for a new or recurrent small tumor.

Chemotherapy and targeted or immune therapies. Systemic treatment, meaning drugs that circulate through the whole body, is frequently paired with stereotactic radiation for a small number of metastases. Timing matters: some drug classes increase the sensitivity of normal tissue to radiation, and the medical oncologist and radiation oncologist will decide together whether to pause, continue or sequence the two. Never adjust a prescribed medication on your own in anticipation of radiation; the prescribing clinician makes that call.

Hormone therapy. In prostate cancer, androgen deprivation therapy, a treatment that lowers testosterone, is sometimes combined with radiation depending on the risk category. Whether it is added is a decision for the urologist and oncologist rather than a candidacy rule for the radiation itself.

Blood thinners and implanted devices. Anticoagulants may need coordination if fiducial markers are being placed, because that step involves a needle. Pacemakers and defibrillators are not a barrier to radiation but require a plan for monitoring, since scattered dose can occasionally affect device electronics (NCI).

The common thread: earlier treatment shapes the plan, but only rarely closes the door.

When is CyberKnife not recommended? Who is usually asked to wait

Being told “not now” or “not this” can feel like a door closing. In practice it usually means a different door is more sensible. These are the situations in which stereotactic radiation is commonly set aside.

Disease that is widespread rather than in a few spots. Stereotactic treatment excels at a handful of lesions. When cancer has spread to many sites, systemic therapy that reaches the whole body becomes the main strategy, and radiation is reserved for spots causing symptoms (NCI).

Tumors that are too large or too diffuse to outline. As discussed, a large mass or one with indistinct borders is generally better served by conventional fractionated radiation, surgery or a combination.

Emergencies that need a surgeon first. A tumor compressing the spinal cord and causing new weakness, or a brain lesion causing dangerous pressure, often needs decompression before any radiation is planned. Radiation takes weeks to act; a surgeon can relieve pressure within hours.

Unclear diagnosis. If imaging cannot distinguish tumor from infection, inflammation or scar, a biopsy may be needed first. Irradiating something that is not a tumor helps no one.

Situations where conventional radiation is simply the standard. For many common cancers, weeks-long radiation to a wider field remains the guideline-supported approach because microscopic disease around the visible tumor needs treating too. Choosing stereotactic delivery in those cases would risk missing the very cells the wider field is designed to catch.

Inability to lie still. Sessions require staying reasonably motionless for up to an hour or more. Severe pain, claustrophobia or breathing difficulty can sometimes be managed with positioning aids or sedation arranged by the team, but occasionally they tip the balance toward shorter conventional sessions.

None of these are judgments about the person. They are matches between a tool and a task, and the task can change as treatment progresses.

CyberKnife vs traditional radiation vs surgery: which fits which situation

Patients often hear these three options described in sequence and come away unsure how they differ. The table summarizes the typical profile of each, drawn from general descriptions published by MedlinePlus, Mayo Clinic and the National Cancer Institute. It describes tendencies, not rules; a tumor board weighs the specifics of each case.

Factor	Robotic SRS / SBRT	Conventional fractionated radiation	Surgery
Typical number of visits	1 to 5 sessions (Mayo Clinic)	Daily sessions over several weeks (NHS)	One operation plus hospital stay
Best-suited target	Small, sharply defined, few in number	Larger areas, or where microscopic spread around the tumor must be covered	Accessible tumors needing removal or tissue diagnosis
Anesthesia or incision	None; mask or body mold for positioning	None	General anesthesia and incision
Previously irradiated area	Often considered for re-treatment because of steep dose fall-off	Usually limited by prior dose	Possible; healing may be slower in irradiated tissue
Speed of effect	Gradual, over weeks to months (Mayo Clinic)	Gradual, over weeks to months	Immediate removal or decompression
Common reasons it is chosen	Awkward location, medical reasons to avoid surgery, retreatment, few metastases	Standard of care for many primary cancers; large or diffuse disease	Emergency pressure relief, need for pathology, large resectable tumors

Two observations from the table deserve emphasis. First, speed is not the same as strength: a five-session course and a six-week course can both be full-intensity treatments aimed at the same outcome, they simply distribute the dose differently. Second, these approaches are frequently combined rather than pitted against each other. Surgery followed by stereotactic radiation to the cavity, or systemic therapy alongside SBRT to a few metastases, are ordinary sequences rather than compromises. When a team recommends the longer conventional course, it is almost always because the biology of the disease calls for a wider net, not because a more modern option was withheld.

CyberKnife for prostate cancer: who tends to be considered

Prostate cancer generates more searches about this technology than any other diagnosis, partly because the prostate has features that make it an interesting target and partly because men face an unusually wide menu of options.

The prostate moves. It shifts with the filling of the bladder and rectum and with breathing, sometimes by several millimeters within a single session. Real-time tracking of fiducial markers placed in the gland is what allows a stereotactic approach to keep tight margins despite that motion (MedlinePlus). The organs at risk, the rectum behind and the bladder above, are the same ones that set limits for every form of prostate radiation, and side effects such as urinary urgency, frequency and bowel irritation are described across all external-beam approaches (NCI).

Candidacy for prostate SBRT is generally discussed in terms of risk category rather than tumor size alone. Risk category combines the PSA level (a blood protein made by the prostate), the Gleason score (a pathologist’s grade of how abnormal the cells look) and the clinical stage. Men with localized disease in the lower and intermediate risk categories are the group in which stereotactic courses have been most widely studied and adopted. Higher-risk disease is more often treated with longer conventional courses, sometimes with pelvic lymph nodes included and hormone therapy added, because the concern extends beyond the gland itself. Whether a shorter course is appropriate in higher-risk cases is an area of active research, and the honest answer is that guideline bodies treat it with more caution.

Factors that tend to push the decision away from SBRT include a very large prostate gland, severe pre-existing urinary symptoms, inflammatory bowel disease affecting the rectum, and prior pelvic radiation. Active surveillance, in which low-risk cancer is monitored rather than treated, remains a guideline-supported alternative for many men and is worth raising explicitly.

Any man weighing these options should expect the urologist and radiation oncologist to discuss them side by side, with the choice resting on his values as much as on his scans.

What the following days and weeks usually look like

Because there is no incision, the aftermath of stereotactic radiation looks less like recovery from an operation and more like a period of watchful waiting with a few predictable bumps.

The first day or two. Most people leave the treatment center within an hour of finishing and resume ordinary activities, including driving if no sedation was used (MedlinePlus). Mild tiredness and, after brain treatment, a headache or nausea are common; the team often prescribes a short course of a steroid medication to limit swelling around the treated area, and that prescription should be taken exactly as directed and never stopped abruptly without checking with the prescriber.

The first few weeks. Fatigue is the most consistent side effect of any radiation and can build over the course of treatment and for a period afterward before easing (NCI). Site-specific effects follow the anatomy: skin redness over a treated spine, cough or chest discomfort after lung SBRT, urinary or bowel irritation after prostate treatment. Hair may thin in a small patch where beams enter the scalp. These effects are usually temporary and are described in detail by the treating team before the first session.

Weeks to months. This is when the treatment actually shows its work. Mayo Clinic notes that results from radiosurgery emerge gradually; benign tumors may take a year or more to show a change on imaging, while cancers generally respond over weeks to a few months. Follow-up scans are scheduled at intervals the team sets, often with the first one a few months after treatment. A lesion that looks larger on an early scan is not necessarily growing; inflammation and swelling can mimic progression, a phenomenon radiologists watch for specifically.

Late effects. A small proportion of people develop radiation necrosis, a patch of damaged tissue at the treatment site, months to years later; it is monitored on imaging and sometimes needs treatment (Mayo Clinic). Knowing the possibility exists makes the follow-up schedule feel less like an inconvenience and more like part of the plan.

What people often get wrong about CyberKnife eligibility

Several myths circulate widely enough that they deserve direct correction.

“It is only for people who cannot have surgery.” Being medically unfit for an operation is one common route to referral, but many candidates could have surgery and choose radiosurgery because of location, because they prefer to avoid an incision, or because their team judges the results comparable for their particular tumor. Fitness for surgery is a factor, not a gatekeeper.

“It has a success rate.” A single figure cannot exist, because the technology treats dozens of conditions with different aims. Control of a benign acoustic neuroma, pain relief from a spinal metastasis and treatment of an early lung cancer are measured in entirely different ways. Anyone quoting one percentage for “CyberKnife” is describing marketing, not medicine. Ask instead for outcomes in your specific diagnosis, stage and situation, and for the guideline or study those numbers come from.

“Fewer sessions means weaker treatment.” The opposite is closer to the truth. Each stereotactic session delivers a far higher dose than a conventional daily fraction; the total biological effect is designed to be at least equivalent. The trade-off is precision requirements, not potency.

“Once I have had radiation, I can never have it again.” As covered earlier, retreatment of a previously irradiated area is one of the specific scenarios in which stereotactic delivery is considered, subject to the details of the earlier course.

“It is painless, so it is risk-free.” The session itself is painless. The biological effects unfold over months and include swelling, fatigue, site-specific irritation and, uncommonly, radiation necrosis. Informed consent is a real conversation, not a formality.

“Newer must be better.” Guideline-supported conventional radiation remains the standard for many cancers precisely because it addresses microscopic spread that a tight stereotactic field would miss. A recommendation for the longer course is a clinical judgment about biology, not a sign of outdated equipment.

Questions to ask your care team before you decide

A consultation goes better when the patient arrives with a short list. These questions are the ones radiation oncologists say they wish more people asked, grouped by what they reveal.

About the recommendation itself

• Why is stereotactic radiation being suggested for me rather than conventional radiation or surgery, and was my case discussed at a tumor board?
• What is the goal: long-term control, symptom relief, or treating a few spots while systemic therapy continues?
• What would you recommend if I were not a candidate, and how does that alternative compare?

About my particular tumor

• How large is the target, what structures sit next to it, and how did those two facts shape the number of sessions you are proposing?
• If I have had radiation before, what dose did the nearby organs receive, and how did that change today’s plan?
• Will I need fiducial markers placed, and what does that involve?

About what to expect

• Which side effects are likely for my treatment site, when do they typically appear, and how long do they usually last?
• Are any of my current medications going to be paused, continued or added around treatment, and who will make that decision?
• How and when will we know whether the treatment worked, and what will the first follow-up scan be looking for?
• What signs should prompt me to call before my next scheduled appointment?

About the bigger picture

• How does this fit with the rest of my treatment plan over the coming year?
• Is a second opinion something you would encourage for my situation?

Write the answers down or bring someone who will. The information density of a radiation consultation is high, and the words that matter most, such as the number of sessions or the name of a side effect to watch for, are easy to lose on the drive home.

When to call your doctor: red-flag signs during and after treatment

Stereotactic radiation is an outpatient treatment, which means the person who first notices a problem is usually the patient or a family member at home. Knowing which symptoms are expected and which are not turns that responsibility into something manageable.

Expected and generally not urgent, though worth mentioning at the next visit: tiredness that builds over a couple of weeks, mild skin pinkness over a treated area, a small patch of hair thinning, mild nausea after brain treatment, or a temporary increase in urinary frequency after prostate treatment (NCI).

Call the treating team the same day, or seek emergency care if symptoms are severe, for any of the following:

• A new or rapidly worsening headache, especially with vomiting, drowsiness or confusion, after brain treatment
• A seizure, even a brief one, in someone who has not had seizures before
• New weakness, numbness or clumsiness in an arm or leg, new difficulty walking, or loss of bladder or bowel control after spine treatment
• Sudden change in vision, double vision, or drooping of the face
• Shortness of breath that is new or worsening, chest pain, or coughing up blood after lung treatment
• A fever above the threshold your team specified, particularly if you are also receiving chemotherapy or immunotherapy
• Severe abdominal pain, black or bloody stools, or vomiting that prevents you from keeping fluids down
• Inability to pass urine, or heavy blood in the urine, after prostate or pelvic treatment
• Any symptom that frightens you and does not settle within the time frame your team described

Keep the after-hours number for the radiation oncology department somewhere visible, and do not wait until the next scheduled appointment to report something on this list. Most calls turn out to be reassuring; the few that do not are the reason the list exists.

Every judgment about whether to continue, pause or change treatment after one of these events belongs to the treating team, who know the plan and the person behind it.

Frequently asked questions

Who is eligible for CyberKnife treatment?

People with a small, clearly defined tumor, benign or malignant, that can be outlined on imaging are the usual candidates, particularly when the tumor sits near sensitive structures, when surgery carries high risk, or when the area has been irradiated before. Common indications include small brain metastases, acoustic neuromas, meningiomas, spinal metastases, early lung cancers and localized prostate cancer. Overall health, the number of lesions and the treatment goal all factor in, and the decision rests with a radiation oncologist working within a multidisciplinary team.

When is a CyberKnife not recommended?

Stereotactic radiation is generally set aside when disease is widespread rather than confined to a few spots, when a tumor is too large or too diffuse to outline precisely, when spinal cord compression or dangerous brain pressure needs urgent surgery first, when the diagnosis is uncertain and a biopsy is needed, or when guidelines call for conventional wide-field radiation to cover microscopic spread. Difficulty lying still for an hour can also shift the plan. Each of these is a matching decision, not a verdict.

What is the success rate of a CyberKnife?

There is no single success rate, because the technology treats many different conditions with different goals, from controlling a benign tumor to relieving pain from a spinal metastasis to treating an early lung cancer. Each is measured differently. Ask your radiation oncologist for outcomes specific to your diagnosis, stage and situation, and for the guideline or systematic review those figures come from. Any single percentage attached to the brand name as a whole is marketing rather than evidence.

Does Medicare pay for CyberKnife radiation?

Coverage for stereotactic radiosurgery and SBRT depends on the specific diagnosis, the documented medical necessity and the rules of the individual plan, whether Medicare, a Medicare Advantage plan or private insurance. This article does not address costs. The reliable route is to ask the treatment center’s billing or financial counseling office to confirm coverage in writing with your insurer before scheduling, and to ask what happens if prior authorization is required or denied.

What are the CyberKnife eligibility criteria my team will actually check?

Expect the team to review the tumor’s size and borders on recent imaging, its distance from critical structures such as the spinal cord, brainstem, optic nerves or bowel, the number of lesions, any prior radiation dose to the same region, previous surgery, current medications including blood thinners, the presence of a pacemaker, your ability to lie still, and the overall treatment goal. Those items are weighed together at a tumor board rather than scored on a checklist.

Can I have CyberKnife if I have already had radiation to the same area?

Often yes, though it depends on details the team will retrieve from your earlier records: the dose delivered, how long ago, which organs were in the field and how they have recovered. The steep dose fall-off of stereotactic delivery is what makes re-irradiation possible in many cases where a broad conventional field would not be safe. Prior radiation to a different part of the body has essentially no bearing on candidacy.

What tumor size is too big for CyberKnife?

For single-session brain radiosurgery, a threshold around 3 centimeters has traditionally been used, roughly the width of a walnut, because larger volumes expose too much surrounding tissue to a high dose. Larger tumors are frequently treated with the same technology across three to five sessions instead. Outside the brain, limits vary by organ and depend on what lies next to the tumor, so the team judges the full three-dimensional picture rather than a single measurement.

Is CyberKnife surgery, and does it involve cutting?

No. Despite the name, nothing is cut and no anesthesia is needed. The word knife refers to the sharp edge of the radiation dose, which falls off steeply at the border of the target. Treatment involves lying on a couch while a robotic arm delivers many focused beams, guided by X-ray images taken throughout the session. Tiny marker seeds are sometimes placed beforehand with a needle to help tracking, which is the only procedure involved.

How many sessions does CyberKnife take, and how long is each one?

Stereotactic radiosurgery is typically delivered in one to five sessions, according to Mayo Clinic, compared with daily sessions over several weeks for conventional radiation. MedlinePlus notes that individual sessions generally last from about 30 minutes to a couple of hours, and most people go home the same day. The exact number depends on tumor size, location and the tolerance of nearby organs, and is set by the radiation oncologist during planning.

Can CyberKnife treat multiple tumors at once?

Yes, a limited number of separate lesions, for example several small brain metastases, can be treated during the same course, sometimes in the same session. Candidacy in this situation depends on the total volume being treated, how close the lesions are to critical structures, and whether systemic therapy is controlling disease elsewhere. When cancer is present at many sites, drug treatment that reaches the whole body usually becomes the main strategy, with radiation reserved for spots causing symptoms.

References

• MedlinePlus: Stereotactic radiosurgery – CyberKnife
• NHS: Radiotherapy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.